For Immediate Release

Chicago, IL – May 6, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Corporate Executive Board (EXBD), Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly (LLY), Alkermes (ALKS) and Pfizer Inc. (PFE).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Tuesday’s Analyst Blog:

Corp. Exec Board Retains Sell Rec

We reiterate our Sell rating on shares of The Corporate Executive Board (EXBD) after the company lowered its full-year outlook in conjunction with its first-quarter earnings release.

The quarterly results were actually above our expectation from an earnings standpoint, as cost-cutting enabled the company to limit the decline in earnings despite a 15% year-over-year decline in revenues.

Cautious on Alkermes’ Surge

Early this morning, Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly (LLY) and Alkermes (ALKS) announced that a New Drug Application (NDA) for Exenatide once weekly for type II diabetes has been submitted to the US FDA.

Exenatide once weekly is an investigational sustained release medication for type II diabetes that is injected subcutaneously and administered only once a week. Exenatide is the active ingredient in Byetta injection, which is currently available on the market for people with type II diabetes who are unable to achieve good glycemic control with common oral therapies. Exenatide once weekly is co-developed by Amylin, Eli Lilly and Alkermes.

PFE Makes Big Bet on Alzheimer’s

Spending on the research and development of Alzheimer’s Disease (AD) treatment and prevention has grown significantly over the last 20 years. The aging baby-boom generation has resulted in a larger population of people at risk for developing the disease.

This, coupled with recent advances in developing drugs that address the underlying cause of the disease versus just treating its symptoms, have been the catalysts for the recent accelerated interest in AD research. Pfizer Inc. (PFE), through partnering arrangements, has been one of the leaders of these efforts.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com

Zacks Investment Research

Last 5 posts by Zacks Market Commentaries

• CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
• Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
• Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
• Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
• GameStop Meets Expectations - Analyst Blog - November 20th, 2009